You are viewing the site in preview mode

Skip to main content

Advertisement

Table 4 Cox univariate analysis showing variables associated with treatment failure during daptomycin-based antimicrobial therapy

From: Daptomycin > 6 mg/kg/day as salvage therapy in patients with complex bone and joint infection: cohort study in a regional reference center

Variable n (%) unadjusted HR (95 % CI) p-value
Age (per 10 years) NA 1.89 (1.03–3.47) 0.041
Male sex 23 (59) 1.48 (0.25–1.48) 0.245
Obesity 12 (31) 1.06 (0.93–1.06) 0.932
ASA score NA 1.11 (0.79–1.11) 0.787
Smoking 13 (33) 0.91 (0.23–3.65) 0.896
Implant associated BJI 33 (85) 27.8 (0.02–40422.69) 0.371
Chronic BJI 5 (13) 1.15 (0.14–9.22) 0.894
Fistula 14 (36) 2.94 (0.60–14.43) 0.185
Relapsing BJI 15 (63) 5.50 (0.69–44.02) 0.108
S. aureus 11 (28) 0.59 (0.12–2.89) 0.517
No or non-optimal surgery 15 (38) 3.63 (0.91–14.73) 0.068
Previous treatment with glycopeptides 34 (87) 25.47 (0.01–142518.48) 0.462
Glycopeptide-resistant isolate 20 (51) 2.965 (0.70–12.58) 0.141
Daptomycin ≤ 8 mg/kg/d 26 (67) 0.676 (0.18–2.55) 0.563
Daptomycin discontinuation for SAE 6 (15) 4.844 (1.17–20.05) 0.029
  1. ASA American Society of Anesthesiologists, BJI bone and joint infection, HR, hazard ratio, NA not applicable (continuous variable), SAE serious adverse events